Curran Terrie, DIR, reported an open-market or private sale at Arcutis Biotherapeutics, Inc. involving 11148.000000 shares for an estimated $279027.75. Reported holdings after the transaction were 23526.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
Form 4 relationship flags and nearby filing context
No officer title
The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.
The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertak…
The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.
The option is fully vested.
0 other filings
0 recent txs